Small Molecules for Chronic Cough, Pain, CNS

Exxel Pharma is dedicated to developing innovative therapeutics aimed at treating neuronal hypersensitivity disorders, with a particular focus on conditions such as chronic cough, neuropathic pain, migraine, and hyperactive bladder. The company's lead program, EX937, is a first-in-class small molecule designed specifically for refractory chronic cough, a condition that currently lacks FDA-approved treatments. EX937 operates through a unique mechanism by inhibiting the fatty acid amide hydrolase (FAAH) enzyme, which has shown promising efficacy and safety in preclinical models. This approach not only targets chronic cough but also has the potential to address other serious medical conditions, highlighting Exxel Pharma's commitment to advancing breakthrough therapeutics.

The development of EX937 is supported by a robust pipeline and a series of preclinical studies that demonstrate its ability to modulate chronic cough effectively while being excluded from the central nervous system, thereby minimizing potential side effects. The company has completed key IND-enabling studies and is currently conducting a Phase 1 study in Australia, which offers various regulatory and financial advantages. Exxel Pharma's innovative approach to targeting FAAH and its focus on addressing significant unmet medical needs position it as a leader in the field of neuronal hypersensitivity disorders, with the potential to transform treatment paradigms for patients worldwide.

United States

Exxel Pharma is a pharmaceutical company focused on the development of innovative, small molecule based medicines for management of pain and treatment of neuronal hypersensitivity disorders.

Exxel Pharma

Company Details